Aquavit Pharmaceuticals Appoints David J. Goldberg as Chief Medical Officer
Aquavit Pharmaceuticals, Inc., appointed David J. Goldberg, MD, JD as its Chief Medical Officer. Dr. Goldberg is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques. Prior to joining Aquavit, Dr. Goldberg has served as President of ASLMS and is and/or was on the Board of Directors of AAD, ASLMS, and ASDS. Additionally, Dr. Goldberg is a Clinical Professor of Dermatology and Director of Laser Research at Mount Sinai School of Medicine, a Clinical Professor of Dermatology and Chief of Dermatologic Surgery at Rutgers New Jersey Medical School as well as the Chief of Dermatology at Hackensack University Medical Center and an Adjunct Professor of Law at Fordham Law School and teaches the "Advances in Health Care Law" course.
"We are thrilled to have Dr. Goldberg on board. He is an exceptional physician, researcher, and most importantly, a visionary with passion in life," said Sobin Chang, CEO of Aquavit Pharmaceuticals. "He is an entrepreneur, a perfect addition to the Aquavit team as we continue to enhance our growing product portfolio."
Dr. Goldberg earned his medical degree from Yale University School of Medicine and completed his dermatology residency and dermatologic surgical fellowship at New York University Medical Center and his law degree from Fordham School of Law. He is a Board certified Dermatologist, having published more than 150 peer-reviewed manuscripts and is author of books on Laser Hair Removal; Cellulite and Fat Removal, Acne and Rosacea, Ablative and Non-ablative Skin Rejuvenation; Photodamaged Skin, Complications in Cutaneous Laser Surgery, Laser Dermatology, and Dermal Fillers. Dr. Goldberg is today Editor in Chief of the Journal of Cosmetic and Laser therapy and serves as an editorial board member of both Lasers in Surgery and Medicine and Dermatologic Surgery. Dr. Goldberg's arrival will provide valuable expertise in advancing Aquavit's strategic research and development commitment to addressing the challenge of unmet need in personalized medicine.